ACTRN12617000840381
Completed
未知
Phase II randomised controlled trial evaluation of treatment decision-aid for patients with bipolar II disorder and their family considering treatment options for relapse prevention.
A/Prof Ilona Juraskova0 sites196 target enrollmentJune 7, 2017
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Bipolar II disorder
- Sponsor
- A/Prof Ilona Juraskova
- Enrollment
- 196
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •i) Confirmed clinical diagnosis of bipolar II disorder;
- •ii) Out of acute episode of depression and/or hypomania (i.e., subsyndromal or euthymic);
- •iii) Actively considering treatment options for relapse prevention in bipolar II disorder with a clinician (e.g., GP, psychiatrist or clinical psychologist).
Exclusion Criteria
- •i) Lacks English proficiency to read the decision\-aid and/or complete questionnaires;
- •ii) Lacks capacity to provide informed consent to research;
- •iii) Comorbid substance abuse disorder;
- •iv) Comorbid neurological or major psychiatric condition.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
eoadjuvant Nivolumab and chemotherapy in stage I-II triple negative breast cancer.Early stage triple negative breast cancerTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-003465-18-ITBreast Cancer Trials108
Active, not recruiting
Phase 1
eoadjuvant Nivolumab and chemotherapy in stage I-II triple negative breast cancer.CTIS2024-512625-86-00ANZ Breast Cancer Trials Group Limited110
Completed
Not Applicable
An exploratory study of dignity therapy for older people in care homesISRCTN37589515King's College London (UK)64
Completed
Phase 2
An exploratory study of Dignity Therapy for people with advanced cancerAdvanced cancerCancerMalignant neoplasm of other and ill-defined sitesISRCTN29868352King's College London (UK)40
Completed
Phase 2
Randomized phase II trial to evaluate the effectiveness of azacitidine for low risk MDS.lower risk myelodysplastic syndromeJPRN-UMIN000010855ational Research Group on Idiopathic Bone Marrow Failure Syndromes100